1 Reason Eli Lilly Stock Is Still a Buy

What: Eli Lilly's diversified portfolio and strong pipeline make it a compelling buy opportunity.
Why: The company's focus on diabetes, oncology, and autoimmune diseases provides a stable foundation for growth.
Signal: Lilly's recent acquisition of Loxo Oncology's $6.5 billion deal signals a significant investment in cancer research.
Target: With a market capitalization of over $**$350 billion**, Eli Lilly is well-positioned for long-term growth and expansion.
Risk: The company's reliance on a few key products, such as Trulicity and Jardiance, poses a risk to revenue if patent expirations occur.